Comparison

Sylfirm X vs Morpheus8

Sylfirm X has a documented pulsed-wave mode marketed for redness and pigment; Morpheus8 goes deeper. Neither clearance names a cosmetic use, and neither device has a published trial of its own.
Written & medically reviewed by the Dermapedia team
At a Glance

Both are radiofrequency microneedling devices: needles into the skin, radiofrequency out of the needle tips. Sylfirm X is made by VIOL in Korea and sold in the US by Benev. Morpheus8 is InMode's.

Sylfirm X's genuine technical difference is that it has two waveforms. Its FDA summary documents continuous-wave modes with conduction times of 120 to 300 milliseconds, and pulsed-wave modes of 120 to 240 milliseconds delivered as four pulses each. That dual-wave design is real and is written into the regulatory paperwork.

What is not in the paperwork is what the pulsed mode is sold for. Sylfirm X is marketed in the US for vascular and pigmentary concerns, including redness and melasma. Its cleared indication says only "intended for use in dermatologic procedures for electrocoagulation and hemostasis" — surgical language for sealing tissue and stopping bleeding. Melasma, redness, rosacea, pigment and vascular lesions appear nowhere in it. Its 2022 clearance actually narrowed the scope, dropping "general surgical procedures."

Morpheus8's clearance names no cosmetic use either. It reads electrocoagulation and hemostasis (2019), then coagulation or contraction of soft tissue (2023). So this is not a case of one device having the paperwork and the other not. Neither does. Treating pigment, redness, scars or laxity with either is off-label, which is legal and routine.

Sylfirm X
VIOL, bipolar, 2 MHz, dual waveform
Morpheus8
InMode, bipolar, 1 MHz

What it is

Bipolar RF microneedling at 2 MHz, with continuous-wave and pulsed-wave modes

Tips include a 25-electrode 5x5 grid and an 18-electrode 3x6 grid.

Bipolar RF microneedling at 1 MHz, with 12-, 24- and 40-pin tips

It is the rebuilt Fractora platform, first cleared in 2011.

Both
Sylfirm X's predecessors and stablemates matter here. Its own predicate devices are CELFIRM and Scarlet SRF, both from the same manufacturer. These machines are more closely related to each other than the marketing suggests.

The mode that gets marketed

Pulsed wave: four short pulses per delivery, 120 to 240 milliseconds, alongside a continuous mode of 120 to 300 milliseconds

This is documented in the 510(k). The claim attached to it, that pulsed mode selectively suits vascular and pigmentary conditions, is not.

Burst mode: radiofrequency fired at several depths during a single needle insertion

The operator manual describes energy released at 7, 5 and 3 mm as the needle retracts. It is a delivery mode, not a separate indication.

Both
Neither mode has a published study isolating it against the same device's standard setting.

How deep it goes

0.3 to 4.0 mm, in 0.1 mm steps

The 0.3 mm minimum is the shallowest documented in this device class.

FDA summaries list 4.0 mm on the 12-pin tip and 7.0 mm on the 24- and 40-pin tips
Both
The shallow end is the part that matters for Sylfirm X's marketed uses, since pigment sits in and just under the epidermis. The deep end is what Morpheus8 is sold on.

What it is cleared to treat

Electrocoagulation and hemostasis, in dermatologic procedures

The 2022 clearance removed "general surgical procedures" from the earlier wording, so the scope narrowed rather than widened.

Electrocoagulation and hemostasis (2019), and coagulation or contraction of soft tissue (2023)

Above 62 mJ per pin, Morpheus8 is limited to skin types I to IV.

Both
Neither clearance names melasma, redness, rosacea, acne scars, wrinkles or laxity. A few devices in this class do carry cosmetic wording - Vivace and Virtue RF for facial wrinkles at 1 MHz, Profound for facial wrinkles and, on its SubQ handpiece, cellulite in Fitzpatrick I to III - but neither of these two is among them.

The needles

Insulation status is not stated in the FDA summary; the manufacturer says the needles are non-insulated
Insulated: the operator manual states the pins are coated except for the distal 0.5 mm
Both
A bare needle shaft carries current at the surface as well as in the dermis, which is the mechanical reason a mark can be left at each entry point. There is no published trial comparing insulated with non-insulated needles in any skin type, so this remains reasoning rather than a measured result.

Evidence behind the badge

No Sylfirm X-specific published trial was found

The melasma research clinics cite is device-agnostic or used other machines. It should not be attributed to this device.

No randomised controlled trial of Morpheus8 was found; a PubMed search returns 16 records in total
Both
The only device-named melasma study in this class used Potenza: a retrospective review of 29 women that missed its primary endpoint, with no significant change in melasma score. One author was employed by the manufacturer and two were company speakers.

Downtime

Not separately measured for this device
Not separately measured for this device
Both
Class figures: redness in 100% and swelling in about 30% of 40 patients in one study, three to four days of downtime in another, and skin barrier measurements back to baseline by day seven.

Who tends to be happy with it

Best for
Someone whose main concern is at the surface, and whose provider wants a very shallow setting and a pulsed delivery.
The mindset
Shallow and repeated, with expectations set by the absence of device-specific evidence.
Best for
Someone whose provider wants to work deep, on the jawline, under the chin or on the body.
The mindset
Depth and contour rather than pigment.

Where the pigment claim stands

This is the part clinics blur, so it is worth separating cleanly.

  • What is documented: Sylfirm X really does have two waveforms, with specific conduction times written into its FDA paperwork.
  • What is marketed: that the pulsed mode is suited to redness, melasma and other pigment problems.
  • What is cleared: electrocoagulation and hemostasis. Nothing about pigment or blood vessels.
  • What is published: no trial of Sylfirm X itself. The RF microneedling melasma literature that exists is device-agnostic, and the one device-named study used a different machine and did not reach significance.

None of that makes the treatment unreasonable. It makes the confidence unreasonable.

Pigment risk, in both directions

Radiofrequency heats by electrical resistance rather than by targeting pigment, which is why this class is generally used more comfortably in deeper skin tones than ablative lasers. In a split-face trial in 2026, RF microneedling produced significantly fewer pigment changes than fractional CO2 laser in the same patients.

But it is not pigment-neutral. Pigment change is the second most reported complication in the FDA's post-market data on RF microneedling: 41 of 224 reported events between 2013 and 2025. That database is voluntary and has no denominator, so it is a share of reports, not a per-patient risk. And Morpheus8's own clearance restricts energies above 62 mJ per pin to skin types I to IV.

If your reason for treatment is melasma, be clear about what is and is not known. Melasma is a stubborn, relapsing condition, and pigment change is the second most reported complication in this device class. Against that, a 20-patient study that followed skin barrier function and melasma severity for six months after microneedle fractional radiofrequency found the melasma severity score unchanged — no exacerbation. There is no trial of Sylfirm X itself either way, so ask for a test area and keep energy conservative.

Before you book

Tell your provider at booking if you get cold sores, because antiviral medication is started in advance rather than after a blister appears. No study has measured cold-sore reactivation after RF microneedling; the practice comes from laser resurfacing.

Ask for a test area if you have deeper skin, ask what energy per pin is planned, and ask about photoprotection during the treatment course. Documented pigment changes after treatment are the reason daily sunscreen is the best-supported piece of aftercare in this whole field.

Get emergency help now

  • Fever after treatment
  • Redness that spreads outward instead of settling
  • Pus or discharge from the treated skin

Call your provider if

  • New brown patches appear in the treated area
  • Existing melasma looks darker or more widespread after treatment
  • A grid of small marks is still visible after about a week
  • Pain, swelling or redness increases after day three
  • A cluster of small painful blisters appears
  • The treated area looks hollowed or sunken in the following weeks

Related

Questions people ask+
Is Sylfirm X FDA cleared for melasma?No. Its cleared indication is "for use in dermatologic procedures for electrocoagulation and hemostasis." Melasma, pigment, redness and vascular lesions appear nowhere in it. Its 2022 clearance actually narrowed the wording rather than adding to it. Using it for melasma is off-label, which is legal and routine.
Is the pulsed-wave mode real, or marketing?The mode is real and documented: the FDA summary lists pulsed settings of 120 to 240 milliseconds delivered as four pulses, alongside continuous settings of 120 to 300 milliseconds. What is marketing is the claim about what that mode treats.
Which one goes deeper?Morpheus8. Sylfirm X runs 0.3 to 4.0 mm. Morpheus8's FDA summaries list up to 4.0 mm on the 12-pin tip and 7.0 mm on the 24- and 40-pin tips. Sylfirm X goes shallower, though: 0.3 mm is the lowest minimum documented in this class.
Which is safer for darker skin?Neither has been tested against the other. Both heat by electrical resistance rather than by targeting pigment, which is the class advantage over ablative lasers. Sylfirm X's clearance sets no skin type limit; Morpheus8's restricts energies above 62 mJ per pin to types I to IV. Energy, density and operator technique matter more than the brand.
Are there studies on Sylfirm X specifically?None were found. The melasma studies clinics cite are device-agnostic or used other machines, and should not be attributed to Sylfirm X. Morpheus8 is barely better off: no randomised controlled trial of it was found either.
Could either make my melasma worse?Nobody can promise it will not. Pigment change is the second most reported complication in FDA post-market data for this device class, and there is no trial of Sylfirm X itself. The one published study that tracked melasma severity for six months after RF microneedling found it unchanged — that is reassuring but small (20 patients) and not device-specific. Ask for a test area, keep energy conservative, and use daily sunscreen throughout the course.
How many sessions, and how long do results last?Published protocols for the class cluster at three sessions three to eight weeks apart, but that is copied convention rather than a tested dose. Six months is the longest properly measured follow-up anywhere in this literature.